Vivo Capital’s OnKure Therapeutics OKUR Stock Holding History

Vivo Capital’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.79M	Hold	1,927,710	–	–	0.8%	31
2026 Q1	$7.98M	Buy	+1,927,710	New	+$5.95M	0.66%	33

Other funds holding OKUR

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vivo Capital's OKUR Position: Q2 2026 in Review

Vivo Capital held its OnKure Therapeutics (OKUR) position steady in Q2 2026 at 1,927,710 shares worth $8.79M. The position accounts for 0.8% of the portfolio, ranked #31.

Vivo Capital first reported a position in OKUR in Q1 2026 and has held it in 2 quarters since. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

Vivo Capital held 1,927,710 shares of OnKure Therapeutics worth $8.79M as of Q2 2026.
Vivo Capital left its OnKure Therapeutics share count unchanged in Q2 2026.
OnKure Therapeutics made up 0.8% of Vivo Capital's portfolio in Q2 2026, its #31 holding.
Vivo Capital first reported a position in OnKure Therapeutics in Q1 2026 and has held it in 2 quarters since.
75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.